The pharmacogenetics of the selective serotonin reuptake inhibitors.

摘要: Citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline are selective serotonin reuptake inhibitors (SSRIs), which thought to act as antidepressants through their ability inhibit presynaptic in the brain. The elimination of SSRIs proceeds predominantly via oxidation catalyzed by cytochrome P450 liver. Paroxetine fluoxetine potent P4502D6 hence may cause serious interactions with drugs metabolized this isozyme, notably tricyclic antidepressants, some neuroleptics, antiarrhythmics. fluvoxamine do not share property. Fluvoxamine is only SSRI that a inhibitor P4501A2 causes pharmacokinetic amitriptyline, clomipramine, imipramine, theophylline, presumably caffeine other isozyme. Citalopram administered racemates, but practically nothing known about stereoselective metabolism two drugs. partially mephenytoin polymorphism, sparteine/debrisoquine polymorphism. pharmacogenetic differences themselves probably no clinical relevance.